“Breakpoint”或称“cut-off” 抗菌药物对细菌MIC值的分布( S、I、R) 3种 “折点 ” 微生物(野生型折点 wild-type Breakpoint )在EUCAST中也称“Microbiological cut-off”, 临床治疗有效标准(折点) 与对引起感染病原体采用抗菌药物治疗成功/失败可能性相关的MIC 在EUCAST也称“epidemiologic cut-off ECOFF...
方法 收集按CLSI标准因产ESBLs而将广谱头孢菌素药敏 结果 由敏感或 中介改为耐药的E.coli和 pneumoniae,用琼脂稀释法检测最低抑菌浓度 (MIC),用CLSI标准和 EUCAST标准 进行敏感性界定。同时用PCR及Hodge.test检测4种ESBLs基因和高活性 13一内酰胺酶。结果 55株茵中53株扩增出介导 ESBLs的相关基因,Hodge.test...
RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook AcronymDefinition CLSIClinical and Laboratory Standards Institute(Wayne, PA) CLSICAD (Computer-Aided Design) Language Systems, Inc. CLSICanadian Light Source Inc.(synchrotron radiation research) ...
Currentsurveillancedatasupportcurrentsusceptiblebreakpoint(≤4ug/ml) 通过耐药监测的数据,支持目前的敏感折点(≤4ug/ml)NomajorshifttohigherMICs;noemergingsubpopulation. 没有MICs升高的趋势,也没有耐药菌株的产生。Twomechanismsofresistancedescribed. 发现了两种新的耐药机制。Workinggrouprecommendsachangeinterminology...
CLSI药敏折点改变的发展趋势 CLSI的简单介绍 •CLSI(ClinicalandLaboratoryStandardsInstitute)是一个全球性的、非盈利的、自愿性质的组织。主要制定医疗相关的规程和标准•是目前医学领域检验和临床实验室公认的标准制定机构。•CLSI致力于全球临床和实验室领域各个方面的标准化和一致化。并且将生产商、政府、医疗机构...
Objectives The aim of this study was to analyse the effects of clinical breakpoint changes in CLSI 2010 and 2011 guidelines and EUCAST 2011 guidelines on antibiotic susceptibility testing (AST) reports. Methods In total, 3713 non-duplicate clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa...
这rino种cultui制ndee度toeps应ttiopn包asnf括eolsr.增teTsh加tiisn实gprao验dtodc室itoiol内nshalo部augld可ent完s成in测-ho试us的eo药rs物end种ing类th或ei必sol须ate送to至ar参efe考re实nce验la室bo的rato菌ry.株。M100-S22.P26 Specimen:TrachealAsspirateDiagnosis:PneumoniaaKlebsiellapneumoniae MIC(...
Breakpoint Change for Enterobacteriaceae and Introduction of the Susceptible-Dose Dependent (SDD) Interpretive Category 18 Summary of CLSI Processes for Establishing Interpretive Criteria and Quality Control Ranges 22 CLSI Reference Methods vs Commercial ...
CLSI M100-S22更新要点
The aims of this study were: (i) to determine the influence of a switch from CLSI to EUCAST methodology on Escherichia coli susceptibility rates; (ii) to compare susceptibility results obtained using EUCAST-compliant microdilution with those from disc diffusion and the Etest; and (iii) to ...